Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 1,900 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 23,300 shares of the biotechnology company’s stock after buying an additional 1,900 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in United Therapeutics were worth $8,221,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in UTHR. Wealth Enhancement Advisory Services LLC boosted its position in shares of United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the period. MBM Wealth Consultants LLC lifted its stake in shares of United Therapeutics by 1.9% during the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 41 shares in the last quarter. UMB Bank n.a. boosted its holdings in United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after buying an additional 51 shares during the period. Access Investment Management LLC increased its stake in United Therapeutics by 0.8% in the 4th quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock worth $2,588,000 after buying an additional 55 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 0.8 %

Shares of NASDAQ:UTHR opened at $358.21 on Tuesday. The company has a market cap of $15.99 billion, a price-to-earnings ratio of 15.73, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company has a 50-day moving average price of $362.39 and a 200 day moving average price of $360.91.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $956,195.85. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 114,164 shares of company stock worth $41,671,293 over the last ninety days. Company insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several research analyst reports. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. LADENBURG THALM/SH SH upped their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.